Skip to main content Skip to main navigation menu Skip to site footer

Post-chemotherapy response of paclitaxel and carboplatin regimens in advanced stage cervical cancer types of histopathology squamous cell carcinoma and adenocarcinoma

  • Yohanes Adhitya Prakasa Sukoco ,
  • Meitria Syahadatina Noor ,
  • Ferry Armanza ,
  • Hariadi Yuseran ,
  • Renny Aditya ,


Background: Cervical cancer incidence in South Borneo was placed 10th in Indonesia. South Borneo Department of Health revealed 1,930 patients diagnosed with cervical cancer in 2019. The main therapy for advanced cervical cancer was radiotherapy, chemotherapy, and combination. This study aims to demonstrate that paclitaxel plus carboplatin regimens have a better post-chemotherapy response in patients with advanced cervical cancer squamous cell carcinoma than adenocarcinoma.

Methods: This study used an analytical observational method with a cross-sectional approach. The sample size was taken during the period during which this study was conducted from January 2015 to December 2020 and was taken by total sampling and divided into 2 groups consisting of patients with advanced cervical cancer, squamous cell carcinoma, and adenocarcinoma histological types. Data were analyzed using SPSS version 21.0 for Windows.    

Results: A total of 202 individuals made up the study's sample, including 54 (26.8%) adenocarcinomas, 148 (73.2%) patients with advanced cervical cancer, and patients with various histological kinds of squamous cell carcinoma. About 107 (52.9%) patients provided complete responses, whereas up to 95 (47.1%) patients provided incomplete responses.

Conclusion: Squamous cell carcinoma, the histological type of cervical cancer, responds to treatment better than adenocarcinoma.


  1. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 2019;393(10167):169-182.
  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
  3. Latifah HJ, Nurachmah, Elly, Hiryadi. Faktor yang Berkontribusi Terhadap Motivasi Menjalani Pemeriksaan Pap Smear Pasien Kanker Serviks di Poli Kandungan. Banjarmasin: Jurnal Keperawatan Suaka Insan. 2020;5(1):90-99.
  4. Bohm ELJF, Hendy J, Hill R, Le Heron J, Mishra K, Trott K, et al. IAEA (International Atomic energy Agency). Radiation Biology: A Handbook For Teachers And Students. Training course Series. Vienna. 2017.
  5. Chiara S, Bruzzone M, Merlini L, Bruzzi P, Rosso R, Franzone P, et al. Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group). Am J Clin Oncol. 1994;17(4):294-297.
  6. Couvreur K, Naert E, Jaeghere E D, Tummers P. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. BMC Cancer. 2018,18(1):1101
  7. Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125(2):292-296.
  8. Andrijono, Purwoto G, Sekarutami SM, Handjari DR, Primariadewi, Nuhonni SA, et al. Kemenkes RI. Pedoman Nasional Pelayanan Kedokteran Kanker Serviks. Jakarta: Komite Penanggulangan Kanker Nasional. 2019.
  9. Gunderson LL and Joel ET. Clinical Radiation Oncology. 3rd Edition. Philadelphia: Elsivier Saunders. 2017:8-29.
  10. Wakatsuki M, Kato S, Ohno T, Banu PA, Hoang NC, Yadamsuren E, et al. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia. Int J Radiation Oncol Biol Phys. 2019;105(1):183-189.
  11. Permana PH, Sulaini P, Hilbertina N. Karakteristik Karsinoma Serviks di RS. Dr. M. Djamil Padang Periode Januari 2010 – Desember 2013. Jurnal Kesehatan Andalas. 2017;6(2):357-363.
  12. Sinaga. Karakteristik Penderita Kanker Serviks [Skripsi]. Medan: Universitas Sumatra Utara; 2017.
  13. Tekalegn Y, Sahiledengle B, Woldeyohannes D, Atlaw D, Desta F, Bekele K, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. Womens Health (Lond). 2022;18:17455065221075904.
  14. Stella NN, Ikechukwu OA. Effect of Age and Parity on Knowledge of Cervical Cancer Screening Among Women of Child Bearing Age in Anambra Stase. Academic Journal of Life Sciences. 2020;6(7):83-92.
  15. Condrat CE, Filip L, Gherghe M, Cretoiu D, Suciu N. Maternal HPV Infection: Effects on Pregnancy Outcome. Viruses. 2021;13(12):2455.
  16. Haryani S, Defrin, Yenita. Prevalensi Kanker Serviks Berdasarkan Paritas di RSUP. Dr. M. Djamil Padang Periode Januari 2011 – Desember 2012. Jurnal Kesehatan Andalas. 2016;5(3):647-652.
  17. Mabuchi S, Isohashi F, Okazawa M, Kitada F, Maruoka S, Ogawa K, et al. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients. J Gynecol Oncol. 2017;28(1):e15.
  18. Qureshi R, Arora H, Rizvi MA. EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett. 2015;356(2 Pt B):321-331.
  19. Iskandar TM, Mexitalia M, Sarjadi, Dharmana E, Pramono N. Respons Histopatologik Karsinoma Serviks Uteri Setelah Pemberian Kemoradiasi. M Med Indones. 2016;45(3):174-180.
  20. Shafiq A. Respon Terapi pada Kanker Serviks Stadium Lanjut yang Mendapat Konkuren Kemoterapi Cisplatin Lengkap dan Tidak Lengkap [Tesis]. Medan: Universitas Sumatra Utara. 2019.
  21. Hu X, Liu H, Ye M, Zhu X. Prognostic value of microvessel density in cervical cancer. Cancer Cell Int. 2018;18:152.
  22. Wulan RN. Hubungan Paritas Dengan Jenis Histo PA Kanker Serviks Di RSUD Dr. Soetomo Surabaya [Thesis]. Surabaya: Universitas Airlangga. 2019.
  23. Hopkins MP, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol. 2016;77(6):912–917.
  24. Tinga DJ, Bouma J, Aalders JG. Patients with squamous cell versus adeno(squamous) carcinoma of the cervix, what factors determine the prognosis? Int J Gynecol Cancer. 2016;2(2):83–91.
  25. Kfouri CFA, Lombard W, Romania MCFN, Puls ML. Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis. Rev Col Bras Cir. 2019;46(1):e2077.
  26. Septiani A, Dewi PPAP, Widyoningroem A, Sensusiati AD, Yamin M. The relationship between Epidermal Growth Factor Receptor (EGFR) mutation and computed tomography findings in lung adenocarcinoma. Bali Medical Journal. 2019;8(2):511-514.

How to Cite

Sukoco, Y. A. P., Meitria Syahadatina Noor, Ferry Armanza, Hariadi Yuseran, & Renny Aditya. (2023). Post-chemotherapy response of paclitaxel and carboplatin regimens in advanced stage cervical cancer types of histopathology squamous cell carcinoma and adenocarcinoma. Bali Medical Journal, 12(1), 799–804.




Search Panel

Yohanes Adhitya Prakasa Sukoco
Google Scholar
BMJ Journal

Meitria Syahadatina Noor
Google Scholar
BMJ Journal

Ferry Armanza
Google Scholar
BMJ Journal

Hariadi Yuseran
Google Scholar
BMJ Journal

Renny Aditya
Google Scholar
BMJ Journal